The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

NACompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

June 30, 2019

Conditions
Symptomatic Aortic Stenosis
Interventions
DEVICE

Embolic Protection Device

Embolic protection

PROCEDURE

Transcatheter aortic valve implantation (TAVI)

Transcatheter aortic valve implantation (TAVI)

Trial Locations (30)

10016

New York University, New York

10032

Columbia University Medical Center/NYPH, New York

11576

St. Francis Hospital, Roslyn

17101

Pinnacle Health, Harrisburg

19104

University of Pennsylvania, Philadelphia

20010

MedStar Washington Hospital Center, Washington D.C.

22903

University of Virginia, Charlottesville

30309

Piedmont Hospital, Atlanta

33016

Delray Medical Center, Hialeah

33756

Morton Plant Hospital, Clearwater

44195

Cleveland Clinic, Cleveland

52242

University of Iowa, Iowa City

60208

Northwestern University, Evanston

70360

Cardiovascular Institute of the South, Houma

75093

Baylor Research Center, Plano

75201

Baylor Heart and Vascular HospitalBaylor Heart and Vascular, Dallas

77030

Houston Methodist Hospital, Houston

University of Texas, Houston

90048

Cedars-Sinai Medical Center, Los Angeles

92122

Foundation for Cardiovascular Medicine, San Diego

98122

Swedish Medical Center, Seattle

06510

Yale New Haven Hospital, New Haven

07960

Morristown Medical Center, Morristown

Unknown

University of Bonn, Bonn

Universitats-Herzzentrum Freiburg, Freiburg im Breisgau

Hamburg Univeristy Cardiovascular Center, Hamburg

Leipzig Heart Institute, Leipzig

San Donato Hospital, Milan

San Rafeele Hospital, Milan

UMC Utrecht, Utrecht

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Keystone Heart

INDUSTRY